ArticleBMC infectious diseases2026
Hepatitis B burden in the Middle East and North Africa region, 1990-2030: trends, projections, and age-period-cohort analysis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B virus (HBV) infection remains a significant public health issue in the Middle East and North Africa (MENA) region, where disparities in healthcare infrastructure, ongoing conflicts, and suboptimal vaccination coverage hinder elimination efforts. This ecological study aimed to assess the temporal trends and age-period-cohort (APC) effects on the HBV-related disease burden across 21 MENA countries (Afghanistan, Algeria, Bahrain, Egypt, Iraq, the Islamic Republic of Iran, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Sudan, the Syrian Arab Republic (SAR), Tunisia, Türkiye, the United Arab Emirates (UAE), and Yemen) from 1990 to 2021 and to forecast future incidence and mortality trends through 2030.
methodsData on incidence, mortality, and disability-adjusted life years (DALYs) were retrieved from the Global Burden of Disease database. Age-standardized incidence rates (ASIRs) and mortality rates (ASMRs) were analyzed by sociodemographic index (SDI) group. APC analysis and autoregressive integrated moving average (ARIMA) models were applied.
resultsFrom 1990 to 2021, new HBV cases increased by 2.8%, deaths increased by 17.8%, and DALYs increased by 11.6%. APC analysis shows a marked decline in HBV-related rate ratios across periods and birth cohorts. The most pronounced reductions were observed in younger birth cohorts and in the post-2015 period, while the burden remained noticeably persistent in older birth cohorts. ARIMA-based projections indicate that by 2030, the ASIR and ASMR are expected to decline by 34.6% and 41.8%, respectively, falling short of the WHO’s 2030 elimination benchmarks.
conclusionsThese findings underscore the critical need to strengthen timely birth-dose and childhood hepatitis B vaccination across the MENA region, together with expanding population-based screening and treatment services and enhancing surveillance systems. In addition, given the substantial heterogeneity in socioeconomic conditions, health-system capacity, and HBV epidemiology across MENA countries, tailored and country-specific strategies are essential. Such context-adapted approaches will be crucial for accelerating progress toward HBV elimination and achieving the WHO 2030 targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.